Brightsurf Science News & Current Events

May 30, 2015
Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer.

SIRFLOX study presented at ASCO 2015 Annual Meeting
Clinical investigators cite significance of 7.9 month improvement in Progression-Free Survival in the liver for patients with unresectable metastatic colorectal cancer treated first line with SIR-Spheres® Y-90 resin microspheres plus chemotherapy.

ESMO announces scale to stratify magnitude of clinical benefit of anticancer medicines
ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale, a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

Removing more breast tissue reduces by half the need for second cancer surgery
Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study.

Study identifies possible new combination chemotherapy for patients with advanced prostate cancer
A role for combination therapy using two or more chemotherapy agents at the same time has not been well studied.

Practice-changing study offers new option for tough breast cancer cases
A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor positive metastatic breast cancer.

Targeted drug can 'diminish the suffering' of myelofibrosis say Mayo Clinic researchers
Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy.

Combining targeted drug with chemotherapy offers longer life to B-cell cancer patients
Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to